1. "Department of Medicine"
Formats
  1. Journal Article (19346)
  2. Meeting Abstract (15822)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39033)
  2. Solid Tumor Oncology Division (22034)
  3. Hematologic Malignancies, Division of (13003)
  4. Center for Hematologic Malignancies (10841)
  5. GSK Faculty (10529)
  6. Survivorship Research (9201)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (642)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39033)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
    Meeting Abstract

    Hofman, M. S.; Gafita, A.; Bressel, M.; Alipour, R.; Levy, S.; Emmett, L.; Ravi Kumar, A. S.; Hamid, A. A.; Buteau, J. P.; Kuo, P. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
    Meeting Abstract

    Fizazi, K.; Morris, M. J.; Shore, N. D.; Chi, K. N.; Crosby, M.; de Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
    Meeting Abstract

    Kelly, W. K.; Appleman, L. J.; Lin, C. C.; Armstrong, A. J.; Fischer, S. C.; Pook, D. W.; Perez Gracia, J. L.; Lee, J. L.; Berthold, D. R.; Ward, P. J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castrationresistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N. J.; Hawley, J.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Nakajima, T.; Moran, D.; Yang, J.; Li, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Wainberg, Z. A.; Van Cutsem, E.; Shitara, K.; Janjigian, Y. Y.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; Tabernero, J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study
    Meeting Abstract

    Clements, H. A.; Dobrzhanskiy, O.; Yang, J.; Bausys, A.; Ferri, L. E.; Ku, G. Y.; Smyth, E. C.; Underwood, T. J.; Petty, R. D.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
    Meeting Abstract

    Kang, Y. K.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Yamaguchi, K.; Nakajima, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
    Meeting Abstract

    Janjigian, Y. Y.; van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save